The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2729-2734

  Giorgi Rossi, Paolo ^a,h   Segnan, Nereo ^b   Zappa, Marco ^c   Naldoni, Carlo ^d   Zorzi, Manuel ^e   Confortini, Massimo ^c   Merito, Monica ^a,f   Cuzick, Jack ^g   Ronco, Guglielmo ^b  

^a Agency for Public Health   (Italy)

^b Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica   (Italy)

^c CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^d Centro di Riferimento Screening   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f SCUOLA SUPERIORE SANT ANNA   (Italy)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h Agenzia di Sanita Pubblica   (Italy)

Author keywords

Cancer screening; Cervical cancer; Costs; Health services workload; Human papilloma virus

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOLOGY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; CYTOPATHOGENIC EFFECT, VIRAL; DIRECT SERVICE COSTS; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PATIENT SELECTION; PUBLIC HEALTH; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 36249029932     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23055     Document Type: Article

References (42)

1. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention No10. Lyon: IARC, 2005.
2. Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen PK, Sparen P, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami HO. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000;60:6027-32.
3. Carozzi F, Ronco G, Confortini M, Noferini D, Maddau C, Ciatto S, Segnan N. Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer 2000;83:1462-7.
4. van den Akker-van Marie ME, van Ballegooijen M, Rozendaal L, Meijer CJ, Habbema JD. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003;89:1830-3.
5. Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, Saville AM. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-32.
6. Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol 2006;107:997-1005.
7. Cochand-Priollet B, Cartier I, de Cremoux P, Le Gales C, Ziol M, Molinie V, Petitjean A, Dosda A, Merea E, Biaggi A, Gouget I, Arkwright S, et al. Cost-effectiveness of liquid-based cytology with or without hybrid-capture II HPV test compared with conventional Pap smears: a study by the French Society of Clinical Cytology. Diagn Cytopathol 2005;33:338-43.
8. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-31.
9. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-95.
10. Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ 2006;332:61-2.
11. Vassilakos P, Petignat P, Boulvain M, Campana A. Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. Br J Cancer 2002;86:382-8.
12. Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol 2002;100:740-8.
13. Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 2005;6:30-7.
14. Moss SM, Gray A, Legood R, Henstock E. First report to the Department of Health on evaluation of LBC (December 2002) http://www.cancerscreening.nhs.uk/ cervical/lbc-pilot-ev. (accessed March 29, 2006).
15. Cervical Screening Wales. Liquid based cytology - pilot project: project report. Cardiff: Velindre NHS Trust, 2003.
16. Scottish Cervical Screening Programme. Steering Group report on the feasibility of introducing liquid based cytology http://www.show.scot.nhs.uk/ publicationsindex.htm (accessed March 22, 2006).
17. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
18. Solomon D, Schiffman M, Tarone R. ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
19. Manos MM, Kinney WK, Hurely LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Rnasley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolau results. JAMA 1999;281:1605-10.
20. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-1876.
21. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-558.
22. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess. 1999;3:1-196.
23. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-1536.
24. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
25. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
26. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
27. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000 17;92:818-25.
28. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
29. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
30. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A. Uribe comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14:505-12.
31. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-77.
32. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC. Evaluation of alternative methods of cervical cancer screening for resource poor settings. Cancer 2000;89:826-83.
33. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, Muller B, Haerting J, Durst M. Screening for high-grade cervical infra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000;89:529-34.
34. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, et al. Human papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trial. J Natl Cancer Inst 2006;98:765-74.
35. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco A, De Lillo M, Naldoni C, Pienotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening among younger women: results at recruitment from the NTCC randomised controlled trial. Lancet Oncol 2006;7:545-53.
36. Koopmanschap MA, Touw KC, Rutten FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001;58:175-86.
37. Zappa M, Cecchini S, Ciatto S, Iossa A, Falini P, Mancini M, Paci E. Measurement of the cost of screening for cervical cancer in the district of Florence, Italy. Tumori 1998;84:631-5.
38. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
39. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC. Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
40. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
41. Karnon J, Peters J, Piatt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8:1-78.
42. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81.